行情

CTSO

CTSO

Cytosorbents
NASDAQ

实时行情|Nasdaq Last Sale

3.400
-0.100
-2.86%
盘后: 3.400 0 0.00% 16:00 01/21 EST
开盘
3.450
昨收
3.500
最高
3.650
最低
3.400
成交量
31.86万
成交额
--
52周最高
11.68
52周最低
3.180
市值
1.48亿
市盈率(TTM)
-9.2467
分时
5日
1月
3月
1年
5年
BRIEF-Cytosorbents Corp- On Jan 19, 2022 Co And Unit Entered Into Amendment To The Amended And Restated Loan And Security Agreement Dated January 19, 2022
reuters.com · 2天前
CytoSorbents Expects Upside FY21 Sales, Despite COVID-19 Headwinds
CytoSorbents Corp (NASDAQ: CTSO) reported preliminary 
Benzinga · 4天前
CytoSorbents jumps 1.86% on prelim FY21 and Q4 revenue above the consensus
CytoSorbents (NASDAQ:CTSO) jumps 1.86% on preliminary FY21 unaudited total revenue of ~$43.2M (consensus $41.95M) versus $41M in 2020. Preliminary FY21 unaudited Product sales were ~$40.1M compared to $39.5M in 2020. Core (non-COVID-19) product
Seekingalpha · 4天前
内部人士是否拥有 Cytosorbents Corporation(纳斯达克股票代码:CTSO)的大量股份?
If you want to know who really controls Cytosorbents Corporation ( NASDAQ:CTSO ), then you'll have to look at the...
Simply Wall St. · 01/12 09:57
BRIEF-Cytosorbents Entered Into Agreement With Jefferies Relating To Sale Of Shares Of Common Stock
reuters.com · 2021/12/30 22:31
Cytosorbents Granted U.S. Patent #11,202,855 ' Methods for removal of toxins from blood using an extracorporeal circuit comprised of a hollow-fiber filter module and polymer sorbent in combination'
View patent here
Benzinga · 2021/12/21 11:37
CytoSorbents Announced Publication of U.S. CTC Multicenter Registry Results Using CytoSorb in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation in Frontiers in Medicine
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the publication of resul...
Benzinga · 2021/12/20 12:11
28 Stocks Moving In Friday's Mid-Day Session
Gainers Genfit SA (NASDAQ: GNFT) shares jumped 33.6% to $4.41 after the company, and Ipsen, announced an exclusive licensing agreement for elafibranor.
Benzinga · 2021/12/17 17:03
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解CTSO最新的财务预测,通过CTSO每股收益,每股净资产,每股现金流等数据分析Cytosorbents近期的经营情况,然后做出明智的投资选择。
分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

33.33%强力推荐
66.67%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测CTSO价格均价为12.50,最高价位15.00,最低价为10.00。
最高15.00
均价12.50
最低10.00
现价3.400
EPS
实际EPS
预期EPS
-0.12-0.09-0.06-0.03
    0
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 143
机构持股: 1,955.69万
持股比例: 44.98%
总股本: 4,347.56万
类型机构数股数
增持
32
117.86万
建仓
9
96.29万
减持
28
99.28万
平仓
15
30.70万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
先进医疗设备和技术
-2.18%
医疗设备和用品
-1.50%
高管信息
Non-Executive Chairman/Independent Director
Al Kraus
President/Chief Operating Officer
Vincent Capponi
Chief Executive Officer/Director
Phillip Chan
Chief Financial Officer
Kathleen Bloch
Chief Scientific Officer
Efthymios Deliargyris
Independent Director
Michael Bator
Independent Director
Edward Jones
Independent Director
Alan Sobel
暂无数据
CTSO 简况
CytoSorbents Corp是一家专注于重症护理的免疫治疗公司。该公司致力于研究血液净化技术并将其商业化,以减少患者无法控制的炎症,并专注于预防或治疗多器官衰竭。该公司的旗舰产品CytoSorb是一种体外细胞因子过滤器,旨在减少在败血症、烧伤、创伤、肺损伤和胰腺炎等常见危重疾病中引起炎症、器官衰竭和死亡的细胞因子风暴。该产品在心脏手术期间和手术后用于清除炎症介质,如细胞因子、活化的补体和游离血红蛋白,其可导致术后并发症,如急性肾损伤、肺损伤、休克和中风。其净化技术基于生物相容性多孔聚合物珠,通过孔隙捕获和表面吸附去除血液和其他体液中的有毒物质。

微牛提供Cytosorbents Corp(NASDAQ-CTSO)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CTSO股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CTSO股票基本功能。